### SUNDAY 10 SEPTEMBER 2017

**13:15-14:45**

**SATELLITE SYMPOSIUM organized by the PREPARE consortium**
An integrated approach to understanding influenza

- **CHAIRS:** Peter Openshaw and Menno de Jong

1. Introduction to the PREPARE consortium, **Menno de Jong**, University of Amsterdam, The Netherlands
2. MOSAIC: a multicentre prospective study of severe influenza, **Long Hoang**, Imperial College London, UK
3. Influenza H1N1pdm infection of healthy volunteers, **Chris Chiu**, Imperial College London, UK
4. Transcriptomics in PREPARE, **Cosimo Cristella**, University of Amsterdam, The Netherlands
5. Is flu a disease of immune failure or excess, **Peter Openshaw**, Imperial College London, UK

**15:00-16:30**

**SATELLITE SYMPOSIUM supported by Vaccines Europe and ESWI**
EU manifesto on influenza vaccination

**16:45-18:15**

**SATELLITE SYMPOSIUM organized by ESPID and ESWI**
Should children be vaccinated against influenza?

- **CHAIR:** Ab Osterhaus, ESWI chair

1. The burden of disease in children, **Pieter Fraaij**, Erasmus MC Rotterdam, The Netherlands
2. Influenza vaccines for children: how effective are they? **Ab Osterhaus**, ESWI chair
4. Universal vaccination of children: the Finnish approach, **Terho Heikkinen**, University of Turku, Finland
5. Should children be routinely vaccinated against influenza and how can we foster the implementation of vaccination recommendations? Panel discussion and audience debate

**18:30-19:30**

**OPENING CEREMONY**

- **WELCOME AND OPENING:**
  - **Ab Osterhaus**, ESWI conference chair

- **PLENARY ADDRESS:**
  - Influenza vaccination as a key public health tool
  - **Vytenis Andriukaitis**, EU Commissioner Health and Food Safety

- **KEYNOTE LECTURE:**
  - A universal influenza virus vaccine
  - **Peter Palese**, Mount Sinai School of Medicine, USA

**19:30-22:00**

**WELCOME RECEPTION**
MONDAY 11 SEPTEMBER 2017

08:30-10:00  PLENARY SESSION

KEYNOTE LECTURE:
H5, H7 influenza viruses: where do we go?
■ Malik Peiris, University of Hong Kong

Maternal immunization against influenza: benefits to mother and child
■ Marta Nunes, University of Witwatersrand, RSA

The use of influenza vaccines reduces antimicrobial resistance
■ Janet McElhaney, Northern Ontario School of Medicine, Canada

10:00-10:45  COFFEE BREAK

10:15-10:45  POSTER SESSION 1 Selection and introduction by Prof. Ab Osterhaus

10:45-12:30  PARALLEL SESSIONS

SPA1  CLINICAL IMPACT AND DIAGNOSTIC APPROACHES
■ CHAIR: Jianqing Xu, Fudan University Shanghai, PRC
■ CO-CHAIR: Cheryl Cohen, National Institute for Communicable Diseases, RSA
1. The clinical impact of routine molecular point-of-care testing for respiratory viruses in hospitalised adults: results of a large pragmatic randomised controlled trial, Tristan Clark, University of Southampton, UK
2. In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa 2009-2013, Cheryl Cohen, National Institute for Communicable Diseases, RSA
3. A Novel Pharmacoeconomic Model to Compare Seasonal Influenza Vaccines in Italian Adults Aged 65 Years and Above, Stefano Capri, Cattaneo-LIUC University, Italy
4. Nasopharyngeal microbial signatures associated with severe influenza in children and in adults, Laurence Josset, Hospices Civils de Lyon, France

SPA2  VIRUS STRUCTURE AND REPLICATION
■ CHAIR: Stephen Cusack, EMBL Grenoble, France
■ CO-CHAIR: Rocío Coloma, Centro Nacional de Biotecnología, Madrid, Spain
1. Analysis of the Higher Order RNA Structures Present Inside the Influenza A Virus Genome, Bernadeta Dadonaite, University of Oxford, UK
2. High-resolution mapping of Influenza A RNA packaging signals by MIME (Mutational Interference Mapping Experiment), Maud Contrant, IBMC, France
3. Structural insights into the mechanisms of influenza A virus RNA replication, Haitian Fan, University of Oxford, UK
4. Mechanistic single-molecule analysis of influenza virus replication, Nicole Robb, University of Oxford, UK

12:30-14:00  LUNCH

SATELLITE SYMPOSIUM organized by SANOFI PASTEUR
Influenza: changing the conversation
■ CHAIR: Marc Van Ranst, University Hospitals of Leuven, Belgium
2. Influenza viruses are constantly evolving: the need for Quadrivalent influenza vaccines, Marc Van Ranst, University Hospitals of Leuven, Belgium
3. Developing a QIV: VaxigripTetra® clinical development, Rosalind Hollingsworth, Global Medical Expert Lead, Influenza, Sanofi Pasteur, Swiftwater, USA
14:00-15:45 PARALLEL SESSIONS

**OMEGA**

**SPA2** EPIDEMICS AND PANDEMIC THREATS

- **CHAIR:** Yoshihiro Kawaoka, University of Wisconsin, USA
- **CO-CHAIR:** Peng Wu, University of Hong Kong, Hong Kong SAR

1. Identification of H1N1 influenza virus survival determinants: amino-acids on the HA protein modulate the stability of viruses in the environment, Thomas Labadie, Institut Pasteur, France
2. Evaluation of potential risk of transmission of Avian Influenza A at the human-animal interface in response to unusual crow die off in Bangladesh, Mahbubur Rahman, Institute of Epidemiology, Disease Control and Research, Bangladesh
3. Outbreak of highly pathogenic avian influenza A virus H5N1 among poultry in Ghana, Ivy Assante, Heinrich-Pette-Institute, Germany
4. Influenza-associated mortality in Yancheng, China, 2011-2015, Qian Xiong, University of Hong Kong, Hong Kong SAR

**SPA3** IMMUNOLOGY

- **CHAIR:** Rafi Ahmed, Emory University, USA
- **CO-CHAIR:** Rory Dylan de Vries, Erasmus MC Rotterdam, The Netherlands

1. First identification of cross-reactive CD8+ T cell immunity across influenza A, B and C viruses, Marios Koutsakos, University of Melbourne, Australia
2. Engaging naive vs. memory B cells in humans: Lessons from H5N1 vaccination, Ali Ellebedy, Emory University, USA
3. Extra-epitopic amino acids influence recognition of the 2009 H1N1 pandemic influenza A virus by CD8+ T cells specific for the conserved M158-66 epitope, Carolien van de Sandt, Erasmus MC Rotterdam, The Netherlands
4. Constitutive TRIM22 expression confers intrinsic antiviral immunity in the respiratory tract, Edward Hutchinson, University of Glasgow, UK

**SPB2** VIRAL FACTORS IN PATHOGENESIS

- **CHAIR:** Adolfo Garcia-Sastre, Mount Sinai School of Medicine, USA
- **CO-CHAIR:** Michelle Tate, University of Melbourne, Australia

1. Factors determining the optimum pH stability for pathogenicity and transmissibility of human influenza viruses, Anika Singanayagam, Imperial College London, UK
2. Variable pathogenicity of H7N7 recombinant viruses in chickens, turkeys and ducks, David Scheibner, Friedrich-Loeffler Institut, Germany
3. Avian-origin PB1 Segment of Influenza A Virus Confers a Parallel Selective Advantage towards Virus Adaptation and Pandemic Formation, Yan Zhou, University of Saskatchewan, Canada
4. Functional analysis of the influenza A virus M2 protein interaction with Na,K-ATPase in influenza pneumonia, Jessica Schulze, Robert Koch Institute, Germany

15:45-16:15 COFFEE BREAK

16:15-18:00 PARALLEL SESSIONS

**OMEGA**

**SPA3** IMMUNOLOGY

1. First identification of cross-reactive CD8+ T cell immunity across influenza A, B and C viruses, Marios Koutsakos, University of Melbourne, Australia
2. Engaging naive vs. memory B cells in humans: Lessons from H5N1 vaccination, Ali Ellebedy, Emory University, USA
3. Extra-epitopic amino acids influence recognition of the 2009 H1N1 pandemic influenza A virus by CD8+ T cells specific for the conserved M158-66 epitope, Carolien van de Sandt, Erasmus MC Rotterdam, The Netherlands
4. Constitutive TRIM22 expression confers intrinsic antiviral immunity in the respiratory tract, Edward Hutchinson, University of Glasgow, UK

**SPB3** MATHEMATICAL MODELING

- **CHAIR:** Colin Russell, Cambridge University, UK
- **CO-CHAIR:** Katelyn Gostic, University of California, USA

1. Population dynamics constrain immune escape in human influenza A, Dylan Morris, Princeton University, USA
2. Estimates of Annual and Average Global Seasonal Influenza-associated Respiratory Mortality form 1999-2015, Angela Iuliano, Centers for Disease Control and Prevention, USA
3. Failing to account for pre-existing immunity against influenza strains leads to an underestimation of influenza vaccine efficacy, Pascal Crépey, Ecole des Hautes Etudes en Santé Publique, France
4. Should we expect broadly protective immunity and childhood hemagglutinin imprinting to impact seasonal influenza epidemiology? Katelyn Gostic, University of California, USA

18:00-19:30 PRIVATE SATELLITE SYMPOSIUM

**OMEGA**

1. First identification of cross-reactive CD8+ T cell immunity across influenza A, B and C viruses, Marios Koutsakos, University of Melbourne, Australia
2. Engaging naive vs. memory B cells in humans: Lessons from H5N1 vaccination, Ali Ellebedy, Emory University, USA
3. Extra-epitopic amino acids influence recognition of the 2009 H1N1 pandemic influenza A virus by CD8+ T cells specific for the conserved M158-66 epitope, Carolien van de Sandt, Erasmus MC Rotterdam, The Netherlands
4. Constitutive TRIM22 expression confers intrinsic antiviral immunity in the respiratory tract, Edward Hutchinson, University of Glasgow, UK
TUESDAY 12 SEPTEMBER 2017

08:00-09:00 SATELLITE SYMPOSIUM COMPANY LECTURES

08:00-08:20 Influenza Hub: Raising awareness about influenza prevention by using social media and innovative engagement techniques
  ■ Philip Weiss, ZN Consulting and Bram Palache, FluPal Consultancy B.V.

08:20-08:40 Treatment of Influenza and RSV –Janssen’s Pipeline in Respiratory Infections
  ■ Jim Witek, Global Franchise Medical Leader, Respiratory Infectious Diseases, Janssen

08:40-09:00 Update on the Clinical Development of Plant-Made Quadrivalent Influenza VLP Vaccine
  ■ Brian J. Ward, Medical Officer for Medicago

09:00-10:00 PLENARY SESSION

KEYNOTE LECTURES:
Clinical management of influenza: where do we go?
  ■ Jonathan Van-Tam, University of Nottingham, UK

Protective and pathological roles of coagulation proteases and PARs in influenza infection
  ■ Nigel Mackman, University of North Carolina at Chapel Hill

10:00-10:45 COFFEE BREAK

10:15-10:45 POSTER SESSION 2 Selection and introduction by Dr. Edward Hutchinson

10:45-12:30 PARALLEL SESSIONS

SPA4 ANTI VIRALS AND RESISTANCE/ MONOCLONAL ANTIBODY THERAPIES
  ■ CHAIR: Elena Govorkova, St. Jude Children’s Research Hospital, USA
  ■ CO-CHAIR: Florian Krammer Mount Sinai School of Medicine, USA
  1. Mechanisms of protection of monoclonal anti-influenza B neuraminidase IgG, IgM and IgA antibodies in a murine challenge model, Veronika Chromikova, Mount Sinai School of Medicine, USA
  2. A Host-Directed Antiviral Approach for Treatment of Influenza Virus Infections, Kelly Warfield, Emergent Biosolutions, USA
  3. Impact of in-hospital neuraminidase inhibitor treatment on length of stay: an Individual Participant Data Meta-analysis, Sudhir Venkatesan, University of Nottingham, UK
  4. Resistance analyses in subjects treated with pimodivir (jn-63623872): results from the phase 2b topaz trial in acute uncomplicated seasonal influenza, Johan Vingerhoets, Janssen, Belgium

SPA4 ANIMAL FLU-ECOLOGY AND EPIDEMIOLOGY OF ANIMAL INFLUENZA
  ■ CHAIR: Gavin Smith, Duke-NUS, Singapore
  ■ CO-CHAIR: Josanne Verhagen, Linnaeus University Växjö, Sweden
  1. Swarm incursions during winter 2016/17 of multiple reassortants of highly pathogenic avian H5N8 influenza strains causing the largest epizootic in birds ever recorded in Germany, Martin Beer, Friedrich Löffler Institut, Germany
  2. Circulation, prevalence and genetic analyses of wild bird avian influenza viruses in a key active surveillance site in Eurasia: 2010-2017, Nicola Lewis, APHA Virology, UK
  3. Circulation of low and highly pathogenic avian influenza A viruses among wild and domestic birds in Ukraine, Denys Myzyka, National Scientific Center Institute of Experimental and Clinical Veterinary Medicine, Ukraine
  4. Mobile poultry vendors in Bangladesh: practices and movement patterns, Ausraful Islam, ICDDR, Bangladesh
12:30-14:00  LUNCH

**SATELLITE SYMPOSIUM organized by SEQIRUS**

Seasonal Influenza in Older Adults: Addressing the challenges and understanding immunization options

1. **Dr. George Kassianos**, President British Global & Travel Health Association and National Immunisation Lead Royal College of General Practitioners
2. **Dr. Paul Van Buynder**, Professor, Griffith University and Chairman, Immunisation Coalition
3. **Dr. Adolfo García-Sastre**, Professor, Icahn School of Medicine at Mount Sinai and Director, Global Health and Emerging Pathogens Institute
4. **Prof. Marco Barbieri**, Honorary Research Fellow, Centre for Health Economics, University of York

14:00-15:45  PARALLEL SESSIONS

**SPA5** VACCINES: CURRENT AND NOVEL APPROACHES

- **CHAIR**: Guus Rimmelzwaan, Erasmus MC Rotterdam, The Netherlands
- **CO-CHAIR**: Ali Ellebedy, Emory University, USA
  1. Nucleoside-modified mRNA vaccination induces influenza virus hemagglutinin stalk-specific antibody responses, **Norbert Pardi**, University of Pennsylvania, USA
  2. Adjuvanted mini-HA induces broadly neutralizing antibodies in pre-exposed non-human primates which protect mice from lethal influenza challenge, **Börries Brandenburg**, Janssen, The Netherlands
  3. Influenza virus hemagglutinin stalk-specific antibodies in human sera measured by ELISA correlate with in vivo protection in a mouse serum transfer model, **Raffael Nachbagauer**, Mount Sinai School of Medicine, USA
  4. Pre-existing orthopoxvirus-specific immunity interferes with T cell responses induced by vaccination with recombinant modified vaccinia virus ankara in mice, **Rory de Vries**, Erasmus MC Rotterdam, The Netherlands

**SPB5** GENETICS AND EVOLUTION OF VIRUS AND HOST

- **CHAIR**: Ron Fouchier, Erasmus MC Rotterdam, The Netherlands
- **CO-CHAIR**: Craig Thompson, University of Oxford, UK
  1. Avian influenza A/H10N7 virus outbreak in seals: identification and characterization of mutations and associated phenotypes driving airborne transmission between ferrets, **Sander Herfst**, Erasmus MC, The Netherlands
  2. Characterization of a newly emerged variant of H7N9 virus containing a polybasic motif in the hemagglutinin protein, **Honglin Chen**, University of Hong Kong, Hong Kong SAR
  3. Polymerase enhancing substitutions that arise during infection with highly pathogenic avian H5N1 influenza in humans, **Dirk Eggink**, Academic Medical Center Amsterdam, The Netherlands
  4. Influenza virus quasispecies characterization of serial upper and lower respiratory tract samples from mechanically ventilated patients, **Björn Koel**, Academic Medical Center Amsterdam, The Netherlands

15:45-16:15  COFFEE BREAK
16:15-18:00

**PARALLEL SESSIONS**

**OMEGA**

**EVALUATION OF VACCINE SAFETY AND EFFECTIVENESS**

**CHAIR:** Maryna Eichelberger, Food and Drug Administration, USA

**CO-CHAIR:** Katja Höschler, Public Health England, UK

1. Efficacy immunogenicity and safety study of a 0.5 ml dose of a quadrivalent inactivated influenza vaccine in children from 6 to 35 months, **Stephanie Pepin**, Sanofi Pasteur, France
2. Assessment of the effect of repeated vaccination on current season influenza vaccine effectiveness (IVE) in patients 60 years old or over, seasons 2013-2014 to 2015-2016 in the Valencia Region, **Víctor Baselga-Moreno**, FISABIO, Spain
3. A new hospital surveillance system in norway for severe influenza in children, **Håkon Bøås**, Institute of Public Health, Norway
4. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine, versus separate administration, in ≥50-year-old adults: results from phase III, randomized, non-inferiority trial, **Geert Leroux-Roels**, University of Ghent, Belgium

**SPB6**

**RISK MANAGEMENT AND MITIGATION OF EPIDEMIC AND PANDEMIC THREATS**

**CHAIR:** Marie-Paule Kieny, World Health Organization

**CO-CHAIR:** Irina Isakova-Sivak, Institute of Experimental Medicine Saint Petersburg, Russia

1. Effect of a reinforced hospital campaign for seasonal influenza vaccination of healthcare workers 2016-2017 on nosocomial outbreaks in the University Hospital of Lyon, France, **Bruno Lina**, University of Lyon, France
2. Partnership for Influenza Vaccine Introduction: early progress in catalyzing influenza vaccine use in low and middle-income countries, **Joseph S. Bresee**, Centers for Disease Control and Prevention, USA
3. Outbreaks of highly pathogenic avian influenza A(H5N5) and A(H5N8) virus infection in birds: National risk assessments and protective measures for humans in 22 EU/EEA countries, 2016/17, **Cornelia Adlhoch**, European Centre for Disease Prevention and Control, Sweden
4. 2016/17 Seasonal Influenza Vaccine Uptake by Medical Students in the UK, **Rachel Groome**, University of Nottingham, UK

18:00-19:30

**SATELLITE SYMPOSIUM** organized by MUGAS Foundation

**NEXT GENERATION INFLUENZA VACCINES: THE FUTURE OF INFLUENZA IMMUNIZATION**

**CHAIR:** Ab Osterhaus, ESWI chair and MUGAS co-founder

1. The need for improved influenza vaccines and adjuvants, **Ab Osterhaus**, ESWI chair and MUGAS co-founder
2. Molecular basis of strain variation, **Ron Fouchier**, Erasmus MC Rotterdam, The Netherlands
3. Pre-emptive vaccine updates and immunity management, **Derek Smith**, Cambridge University, UK
4. Mammalian Cell Culture and the Evolution of the Influenza Vaccine System, **Ethan C. Settembre**, Seqirus, Cambridge, MA, USA
5. The plant-based Proficia™ technology, a rapid and efficient platform for the production of influenza VLP vaccines, **Nathalie Charland**, Senior Director, Scientific & Medical Affairs for Medicago
6. Influenza adjuvanted surface low-dose Grippol® Quadrivalent vaccine immunogenicity, safety and efficacy, **Marina Abramova**, Vice President, NPO Petrovax Pharm
7. The revolution in influenza vaccine manufacturing: The B.E.S.T. platform used to produce Flublok®, **Manon Cox**, President and CEO, Protein Sciences

20:00-22:00

**FAREWELL DINNER**
**WEDNESDAY 13 SEPTEMBER 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:15</td>
<td><strong>PL04 YOUNG SCIENTISTS PLENARY SESSION</strong>&lt;br&gt;<strong>CHAIR:</strong> Ed Hutchinson, University of Glasgow, UK</td>
</tr>
<tr>
<td>09:15-10:00</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>POSTER SESSION 3 Selection and introduction by by Prof. Gulsah Gabriel</strong></td>
</tr>
<tr>
<td>10:00-11:45</td>
<td><strong>PARALLEL SESSIONS</strong>&lt;br&gt;<strong>SPA7 MATERNAL AND CHILDHOOD IMMUNIZATION</strong>&lt;br&gt;<strong>CHAIR:</strong> Terho Heikkinen, University of Turku, Finland&lt;br&gt;<strong>CO-CHAIR:</strong> Marta Nunes, University of Witwatersrand, RSA&lt;br&gt;1. Seroprevalence of seasonal influenza virus infection among unvaccinated pregnant women in Bangladesh, 2013-2014, Zubair Akhtar, ICDDR, Bangladesh&lt;br&gt;2. Influenza A virus infection during pregnancy: high progesterone levels during pregnancy increase mortality in pregnant influenza infected mice by impairing the anti-viral immune response, Alexandra Hierweger, University Medical Center Hamburg-Eppendorf, Germany&lt;br&gt;3. A randomised controlled trial to increase influenza vaccine uptake in children aged from 6 to 24 months, Karene Yeung, The Chinese University of Hongkong, Hong Kong SAR&lt;br&gt;4. Assessing direct and indirect effects of pediatric influenza vaccination in Germany using individual-based simulations – Epidemiological considerations, Ruprecht Schmidt-Ott, GlaxoSmithKline, Germany</td>
</tr>
<tr>
<td>11:45-12:15</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>11:45-12:15</td>
<td><strong>SPB7 HOST FACTORS IN PATHOGENESIS</strong>&lt;br&gt;<strong>CHAIR:</strong> Gulsah Gabriel, Heinrich Pette Institute Hamburg, Germany&lt;br&gt;<strong>CO-CHAIR:</strong> Ivan Marazzi, Mount Sinai School of Medicine, USA&lt;br&gt;1. Emergence of Highly Virulent H1N1 Influenza Virus Strains in Allogenically Pregnant Mice, Stephanie Bertram, Heinrich Pette Institute, Germany&lt;br&gt;2. SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses, Alexandra Dudek, Institute of Virology Freiburg, Germany&lt;br&gt;3. Resistance to influenza A infections in mice carrying deletions in host protease genes, Klaus Schughart, Helmholtz Centre for Infection Research, Germany&lt;br&gt;4. The role of obesity in the generation of influenza virus quasispecies, Kirsty Short, University of Queensland, Australia</td>
</tr>
</tbody>
</table>
12:15-13:45  PLENARY SESSION - LATE BREAKERS

- CHAIR: Sylvie van der Werf, Institut Pasteur Paris, France
- CO-CHAIR: Susanne Herold, University of Giessen, Germany

1. Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza in Otherwise Healthy Adolescents and Adults with Seasonal Influenza, Frederick Hayden, University of Virginia School of Medicine, Charlottesville, Virginia, USA

2. The OPAL Trial: A Placebo-controlled Trial Studying Pimodivir (Formerly JNJ-63623872 or VX-787) plus Oseltamivir vs. Placebo plus Oseltamivir in Adult and Elderly Hospitalized Patients with Influenza A Infection, Brian O’Neil, Wayne State University School of Medicine, United States of America

3. Targeting the pro-viral host factor, focal adhesion kinase (FAK), limits influenza A virus infections and NFkB regulated pro-inflammatory responses in vivo and in vitro, Silke Bergmann, Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

4. Efficacy and Safety of Oseltamavir in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials, Arnold S Monto, University of Michigan School of Public Health, United States of America

13:45-14:30  LUNCH
### SUNDAY 10 SEPTEMBER 2017

**13:15-14:45**
**SATellite Symposium organized by the PREPARE consortium**
An integrated approach to understanding influenza

- **CHAIRS:** Peter Openshaw and Menno de Jong
- 1. Introduction to the PREPARE consortium, Menno de Jong, University of Amsterdam, The Netherlands
- 2. MOSAIC: a multicentre prospective study of severe influenza, Long Hoang, Imperial College London, UK
- 3. Influenza H1N1pdm infection of healthy volunteers, Chris Chiu, Imperial College London, UK
- 4. Transcriptomics in PREPARE, Cosimo Cristella, University of Amsterdam, The Netherlands
- 5. Is flu a disease of immune failure or excess, Peter Openshaw, Imperial College London, UK

**15:00-16:30**
**SATellite Symposium supported by Vaccines Europe and ESWI**
EU manifesto on influenza vaccination

**16:45-18:15**
**SATellite Symposium organized by ESPID and ESWI**
Should children be vaccinated against influenza?

- **CHAIR:** Ab Osterhaus, ESWI chair
- 1. The burden of disease in children, Pieter Fraaij, Erasmus MC Rotterdam, The Netherlands
- 2. Influenza vaccines for children: how effective are they? Ab Osterhaus, ESWI chair
- 4. Universal vaccination of children: the Finnish approach, Terho Heikkinen, University of Turku, Finland
- 5. Should children be routinely vaccinated against influenza and how can we foster the implementation of vaccination recommendations? Panel discussion and audience debate

**18:30-19:30**
**OPENING CEREMONY**

- **WELCOME AND OPENING:** Ab Osterhaus, ESWI conference chair
- **PLENARY ADDRESS:** Influenza vaccination as a key public health tool, Vytenis Andriukaitis, EU Commissioner Health and Food Safety
- **KEYNOTE LECTURE:** A universal influenza virus vaccine, Peter Palese, Mount Sinai School of Medicine, USA

**19:30-22:00**
**WELCOME RECEPTION**
### MONDAY 11 SEPTEMBER 2017

**08:30-10:00**

**PLENARY SESSION**

**KEYNOTE LECTURE:**

- **H5, H7 influenza viruses: where do we go?**
  - Malik Peiris, University of Hongkong

- **Maternal immunization against influenza: benefits to mother and child**
  - Marta Nunes, University of Witwatersrand, RSA

- **The use of influenza vaccines reduces antimicrobial resistance**
  - Janet McElhaney, Northern Ontario School of Medicine, Canada

**10:00-10:45**

**COFFEE BREAK**

**10:15-10:45**

**POSTER SESSION 1**

*Selection and introduction by Prof. Ab Osterhaus*

**10:45-12:30**

**ALL YOU NEED TO KNOW ABOUT INFLUENZA VIRUSES**

- **CHAIR:** Ab Osterhaus, RIZ Hannover, Germany

  1. All you need to know about influenza viruses, Ab Osterhaus, RIZ Tiho Hannover, Germany
  2. Close focus: vaccines and antivirals, Florian Krammer, Mount Sinai School of Medicine, USA
  3. How flu viruses travel around the world, Colin Russell, University of Cambridge, UK
  4. Who is at risk of flu infections and are these risk groups well-protected? ECDC informs, Pasi Penttinen, ECDC
  5. The economic impact of flu: WHO informs, Caroline Brown, WHO Europe

**12:30-14:00**

**LUNCH**

**14:00-15:45**

**PREVENTION AND TREATMENT OF INFLUENZA**

- **CHAIR:** Jonathan Van-Tam, University of Nottingham, UK

  1. Vaccines: current and novel approaches, Guus Rimmelzwaan, Erasmus MC Rotterdam, The Netherlands
  2. Effectiveness of seasonal and pandemic influenza vaccines, Jonathan Van-Tam, University of Nottingham, UK
  3. Safety of seasonal and pandemic influenza vaccines, Michael McNeil, CDC Immunization Safety Office, USA
  5. Safety and effectiveness of influenza antivirals, Nicole Bouvier, Mount Sinai School of Medicine, USA

**15:45-16:15**

**COFFEE BREAK**

**16:15-18:00**

**ADDRESSING INFLUENZA IN PRACTICE: WHO’S INVOLVED?**

- **CHAIR:** Susanne Herold, University of Giessen, Germany

  1. Family doctors: our trusted advisors, Ted van Essen, general practitioner, The Netherlands
  2. Protecting healthcare workers and patients in hospital settings, Roman Prymula, University Hospital Hradec Králové, Czech Republic
  3. Nurses and midwives: in the forefront in the fight against flu, Agita Melbārde-Kelmere, European Forum of National Nursing and Midwifery Associations (EFNMA), Latvia
  4. The new role of pharmacists in flu prevention, Isabel Jacinto, National Association of Pharmacies, Portugal
  5. Respiratory physicians tackling influenza, Susanne Herold, University of Giessen, Germany

**18:00-19:30**

**PRIVATE SATELLITE SYMPOSIUM**

---
## TUESDAY 12 SEPTEMBER 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td><strong>SATELLITE SYMPOSIUM</strong> <strong>COMPANY LECTURES</strong></td>
</tr>
</tbody>
</table>
| 08:00-08:20   | Influenza Hub: Raising awareness about influenza prevention by using social media and innovative engagement techniques  
**Philip Weiss**, ZN Consulting and **Bram Palache**, FluPal Consultancy B.V. |
| 08:20-08:40   | Treatment of Influenza and RSV – Janssen’s Pipeline in Respiratory Infections  
**Jim Witek**, Global Franchise Medical Leader, Respiratory Infectious Diseases, Janssen |
| 08:40-09:00   | Update on the Clinical Development of Plant-Made Quadrivalent Influenza VLP Vaccine  
**Brian J. Ward**, Medical Officer for Medicago |
| 09:00-10:00   | **PLENARY SESSION** **OMEGA**                                                             |
| 10:00-10:45   | **COFFEE BREAK**                                                                          |
| 10:15-10:45   | **POSTER SESSION 2** Selection and introduction by Dr. Edward Hutchinson                  |
| 10:45-12:30   | **IMPLEMENTATION OF VACCINATION POLICIES: SUCCESS STORIES AND HURDLES** **BETA**          |
| 12:30-14:00   | **LUNCH**                                                                                |

**SATELLITE SYMPOSIUM organized by SEQIRUS**  
Seasonal Influenza in Older Adults: Addressing the challenges and understanding immunization options

1. **Dr. George Kassianos**, President British Global & Travel Health Association and National Immunisation Lead Royal College of General Practitioners  
2. **Dr. Paul Van Buynder**, Professor, Griffith University and Chairman, Immunisation Coalition  
3. **Dr. Adolfo García-Sastre**, Professor, Icahn School of Medicine at Mount Sinai and Director, Global Health and Emerging Pathogens Institute  
4. **Prof. Marco Barbieri**, Honorary Research Fellow, Centre for Health Economics, University of York
14:00-15:45  **INFLUENZA PREPAREDNESS: WHAT CAN WE LEARN FROM OTHER VIRUS OUTBREAKS?**  

**CHAIR**: Marc Van Ranst, University of Leuven, Belgium  
1. Ebola: what went wrong and where do we go now? **Guido van der Groen**, Prof. Em. Institute for Tropical Medicine in Antwerp, Belgium  
2. How to successfully prevent a major disease outbreak: from SARS to MERS, **Ab Osterhaus**, RIZ Tiho Hannover, Germany  
3. Zika virus as a global public health emergency, **Herve Zeller**, head of disease programme for Emerging and vector-borne diseases, ECDC  
4. The H1N1 health crisis: how did we cope and are we prepared for a new outbreak? **Marc Van Ranst**, University of Leuven, Belgium  
5. Revised pandemic preparedness plans and global update on PIP Framework, **Wenqing Zhang**, Global Influenza Programme, World Health Organization, Switzerland

15:45-16:15  **COFFEE BREAK**

16:15-18:00  **REACHING OUT TO PEOPLE AT RISK**  

**CHAIR**: Litjen Tan, Immunization Action Coalition, USA  
1. Should children be vaccinated against influenza? **Adam Finn**, University of Bristol, UK and president ESPID  
2. Should travellers be vaccinated against flu? **Marco Goeijenbier**, Harbour Hospital Rotterdam, The Netherlands  
3. Protecting diabetes patients against flu, **Perry van Genderen**, Harbour Hospital Rotterdam, The Netherlands  
4. Reaching out to the elderly: why and how, **Janet McElhaney**, Northern Ontario School of Medicine, Canada  
5. Vaccinating pregnant women against influenza, **Erin Sparrow**, (WHO)  
6. The benefits of a universal vaccination recommendation: the US case, **Litjen Tan**, Immunization Action Coalition, USA

18:00-19:30  **SATELLITE SYMPOSIUM organized by MUGAS Foundation**  

**NEXT GENERATION INFLUENZA VACCINES: THE FUTURE OF INFLUENZA IMMUNIZATION**  

**CHAIR**: Ab Osterhaus, ESWI chair and MUGAS co-founder  
1. The need for improved influenza vaccines and adjuvants, **Ab Osterhaus**, ESWI chair and MUGAS co-founder  
2. Molecular basis of strain variation, **Ron Fouchier**, Erasmus MC Rotterdam, The Netherlands  
3. Pre-emptive vaccine updates and immunity management, **Derek Smith**, Cambridge University, UK  
4. Mammalian Cell Culture and the Evolution of the Influenza Vaccine System, **Ethan C. Settembre**, Seqirus, Cambridge, MA, USA  
5. The plant-based Proficia™ technology, a rapid and efficient platform for the production of influenza VLP vaccines, **Nathalie Charland**, Senior Director, Scientific & Medical Affairs for Medicago  
6. Influenza adjuvanted surface low-dose Grippol® Quadrivalent vaccine immunogenicity, safety and efficacy, **Marina Abramova**, Vice President, NPO Petrovax Pharm  
7. The revolution in influenza vaccine manufacturing: The B.E.S.T. platform used to produce Flublok®, **Manon Cox**, President and CEO, Protein Sciences

20:00-22:00  **FAREWELL DINNER**
## WEDNESDAY 13 SEPTEMBER 2017

### 08:00-09:15

**PL04 YOUNG SCIENTISTS PLENARY SESSION**

- **CHAIR:** Ed Hutchinson, University of Glasgow, UK
- **CO-CHAIR:** Claude Hannoun, Institut Pasteur Paris, France

**Speakers:**
1. Debby van Riel, ESWI Best Body of Work award winner 2017
2. Matthew S. Miller, Best Oral Presentation ESWI 2014
3. Steven F. Baker, Best Poster Presentation ESWI 2014
4. Karen Laurie, Award Winner Orthomyxovirus Research Conference 2015
5. Jason Long, Award Winner Orthomyxovirus Research Conference 2015

### 09:15-10:00

**COFFEE BREAK**

### 09:30-10:00

**POSTER SESSION 3 Selection and introduction by by Prof. Gülsah Gabriel**

### 10:00-11:45

**SP17 INFLUENZA PREVENTION IN DEVELOPING COUNTRIES: A GLOBAL RESPONSIBILITY**

- **CHAIR:** Malik Peiris, University of Hong Kong

1. How to protect mother and child, Abdullah Brooks, Infectious Diseases Unit at Kamalapur Field Site, Bangladesh
2. Global access to influenza vaccines for LMIC - challenges and opportunities, Niteen Wairagkar, Bill & Melinda Gates Foundation
3. Logistical challenges in low income countries, Mark McCaul, Supply Chain Officer at Médecins Sans Frontières
4. Can we prevent severe outcomes through influenza vaccination? Cheryl Cohen, National Institute for Communicable Diseases, RSA

### 11:45-12:15

**COFFEE BREAK**

### 12:15-13:45

**PL05 PLENARY SESSION - LATE BREAKERS**

- **CHAIR:** Sylvie van der Werf, Institut Pasteur Paris, France
- **CO-CHAIR:** Susanne Herold, University of Giessen, Germany

1. Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza in Otherwise Healthy Adolescents and Adults with Seasonal Influenza, Frederick Hayden, University of Virginia School of Medicine, Charlottesville, Virginia, USA
2. The OPAL Trial: A Placebo-controlled Trial Studying Pimodivir (Formerly JNJ-63623872 or VX-787) plus Oseltamivir vs. Placebo plus Oseltamivir in Adult and Elderly Hospitalized Patients with Influenza A Infection, Brian O’Neil, Wayne State University School of Medicine, United States of America
3. Targeting the pro-viral host factor, focal adhesion kinase (FAK), limits influenza A virus infections and NFκB regulated pro-inflammatory responses in vivo and in vitro, Silke Bergmann, Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
4. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials, Arnold S Monto, University of Michigan School of Public Health, United States of America

### 13:45-14:30

**LUNCH**